Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates - Wikidata - wikimedia - TriplyDB

Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates

Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates

http://www.wikidata.org/entity/Q21131585

about

Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates Current ebola vaccines Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates Ebola Vaccination: If Not Now, When?Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe A Recombinant Vesicular Stomatitis Virus Ebola Vaccine — Preliminary Report Emerging targets and novel approaches to Ebola virus prophylaxis and treatment Ebola haemorrhagic fever Clinical development of Ebola vaccines Ebolavirus glycoprotein structure and mechanism of entry Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target Characterization of a Bivalent Vaccine Capable of Inducing Protection Against Both Ebola and Cross-clade H5N1 Influenza in Mice Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge.Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product.Ethics review of studies during public health emergencies - the experience of the WHO ethics review committee during the Ebola virus disease epidemic.A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose.Ebola virus disease: an update for anesthesiologists and intensivists.Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus.Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick.Ebola vaccine R&D: Filling the knowledge gaps.Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.DNA vaccines for biodefense.Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy.Structures of protective antibodies reveal sites of vulnerability on Ebola virus.Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice.Filovirus emergence and vaccine development: a perspective for health care practitioners in travel medicine Next-generation sequencing reveals a controlled immune response to Zaire Ebola virus challenge in cynomolgus macaques immunized with vesicular stomatitis virus expressing Zaire Ebola virus glycoprotein (VSVΔG/EBOVgp).Good and bad news about Ebola.Safety of recombinant VSV-Ebola virus vaccine vector in pigs.Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus.Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection Ebolavirus in West Africa, and the use of experimental therapies or vaccines.Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus.Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections Filovirus vaccines.

P2860

Q21090120-14BA23F9-9895-4BD2-A528-B44986F98030 Q21534720-C165DD06-164B-4261-8F1C-E27E7F2BA675 Q21559476-3BA489AF-DB06-4AD3-845E-BF024128FD4A Q22305299-E1FFBC86-B3C6-4C05-BE8D-1DA8E0B2C43A Q24289281-711161CD-1B28-4F1F-9E64-022123F8BD20 Q24289295-B8627503-6E9F-4463-97DD-A934D07732B2 Q24597625-7A719117-1480-4637-B291-E5DE89C9FF13 Q24629338-DD9DC340-C985-4C1A-B9C6-37EE2645E1CA Q26775792-9CBFF51C-4A59-4E49-8C7C-850A80FA1BCC Q27490991-F70D7712-9C15-4C3F-A56E-A178607D740F Q28051937-A36A7F13-84AD-4966-B2AB-04268919AE58 Q28223031-8C712A12-BCB4-4B14-82B6-B843B8196528 Q30227194-7C7CE768-CDD2-4C49-9D12-6AA29A1924F5 Q30375073-4FB88063-6A5A-4CE3-840C-2068D7CABE19 Q30382097-63752B20-A051-4AEF-AD1C-5A1622685047 Q30385999-1E04A1AA-5EC6-4F1C-834D-FF9434EE8738 Q30427591-5072D009-86BB-44F5-A10B-BEF2FF1389C0 Q33818337-B3A93354-8835-4C3F-9635-4ED5EBF11BF7 Q33826350-254CBFA4-8583-4C2C-9544-52F71BD9CA53 Q33837161-198DA0FC-7D37-4DAB-B789-C843365B47BE Q33964081-F6372457-062A-4934-BA7C-BBBF9611D61F Q34446478-E2BD78B6-E102-4164-AA92-BBD5E33ABE90 Q34463780-3B24B387-A8C7-48B5-ABCE-5B66043E9913 Q34465812-4676DFC5-A08F-40A8-9E27-EECD4501A061 Q34504883-FC8E786A-9FF7-46EC-8B7D-77818B3AFDF0 Q34606818-9D2CB485-3546-4E1B-912F-5A91D60DC7B5 Q34614260-2FF8EB22-B207-4F58-8A32-87DD348447EB Q34632946-6D045797-CF40-431D-BD40-79AC9D15C4BD Q34661120-44D30990-5A69-4946-8374-0BEB10C33665 Q34761889-F766B777-29D1-4259-AEC3-16CB7A21B4D3 Q35048254-CC7C20E7-F576-4BA2-8EB5-33F325426E4B Q35122795-E346A538-9628-4024-8FEB-7BA5737EEAA3 Q35170902-E7A5F753-15A2-4D61-9B51-30FE9618C6B7 Q35229679-789EE96E-951C-4768-9B83-6CC566CF8424 Q35300062-F569AAAE-2B8F-4995-80F8-9DF6000C59BE Q35300104-6FA95EC5-B9D2-4163-90B8-688A2994D6C2 Q35305323-2870565D-693C-440F-A67C-7FFAAD481E72 Q35531542-B99DF840-A1AA-4C75-A12C-B9350E1896BF Q35557184-2D049419-CF0B-4AE7-975D-FC280371EBFE Q35558539-476DF6A1-7F69-48B6-827F-12FECDF3A9FE

P2860

Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates

http://www.wikidata.org/entity/Q21131585

description

2008 nî lūn-bûn

@nan

2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Vesicular stomatitis virus-bas ...... ocompromised nonhuman primates

@ast

Vesicular stomatitis virus-bas ...... ocompromised nonhuman primates

@en

Vesicular stomatitis virus-bas ...... ocompromised nonhuman primates

@en-gb

Vesicular stomatitis virus-bas ...... ocompromised nonhuman primates

@nl

type

label

Vesicular stomatitis virus-bas ...... ocompromised nonhuman primates

@ast

Vesicular stomatitis virus-bas ...... ocompromised nonhuman primates

@en

Vesicular stomatitis virus-bas ...... ocompromised nonhuman primates

@en-gb

Vesicular stomatitis virus-bas ...... ocompromised nonhuman primates

@nl

prefLabel

Vesicular stomatitis virus-bas ...... ocompromised nonhuman primates

@ast

Vesicular stomatitis virus-bas ...... ocompromised nonhuman primates

@en

Vesicular stomatitis virus-bas ...... ocompromised nonhuman primates

@en-gb

Vesicular stomatitis virus-bas ...... ocompromised nonhuman primates

@nl

P1433

Q21131585-4B5C13C0-A81F-42E3-BD29-84310B22339C

P1476

Q21131585-1469E3D5-6D44-4275-908B-816668F41E97

P2093

Q21131585-03A2EEFD-7583-4AE9-8E51-E81B266FC02F

Q21131585-0DC73216-C2FA-4E56-ABD2-8149FC5177AE

Q21131585-2E50A125-B5E7-4AFF-90A9-8F01BA0F5571

Q21131585-50C8AC87-72CB-4584-953A-7D3C4E50792E

Q21131585-61D144ED-D51B-432C-A108-D80C4C673356

Q21131585-6BB1D663-602F-4DB0-8F2A-2EBCDEB3C0AB

Q21131585-A6E9998E-2912-45A4-957E-3FEC339CADFB

Q21131585-AAEE81F8-1411-4F93-B0A4-2CBAB5CDAC5B

P2860

Q21131585-053FF74D-E60E-414A-BE4D-FB6375D119C6

Q21131585-088691F4-3DEA-4D4A-8639-81E5F3E0360C

Q21131585-0F516A0D-3271-4AF7-A99B-88498FF7E312

Q21131585-1A2A59DE-3689-44D2-B057-F36475F70596

Q21131585-1B07DEA9-9359-4D27-8513-82D55289FE3F

Q21131585-21A7F116-72E4-4962-9049-1C9EEB503548

Q21131585-2A6B4D65-0CE7-4BD5-A7D6-CD5B84CC53A8

Q21131585-2BE40127-40BC-46A7-BFA4-DD1EA129CD45

Q21131585-322EC0B5-C844-4FC8-B8D8-18C21F273EEF

Q21131585-3926C7C1-6F89-4984-B151-7EDE8EFBC975

P304

Q21131585-E7917D98-E852-4260-9C0E-E998C6CC67D5

P31

Q21131585-07971203-EFE0-43C0-A3AB-5E5F1A83B533

P356

Q21131585-A5ED3919-C24F-4821-A8B0-2ADC1857AB97

P407

Q21131585-3E440C62-FABB-456D-BAA1-FA13ACD19E7C

P433

Q21131585-99AA78AB-4562-4B90-87CA-D6CA9C331592

P478

Q21131585-2EE05A69-5A2D-4626-88A8-CA0EC97FFD6C

P50

Q21131585-1807FC07-52C6-4C06-BB94-3E0F41019318

Q21131585-1F8CE443-EF7F-4B8E-888F-1C83CFB954C9

Q21131585-8D721355-6961-44EF-B551-1E389D391185

Q21131585-BA54AA17-13D5-4440-B11F-F8AEEE4A3AF4

Q21131585-FDE5C3F6-F9A4-4D34-ABE6-3C45CF20E0C6

P577

Q21131585-4A162C04-C760-422D-A7E2-1650AD0857E4

P5875

Q21131585-FD638384-A82C-4BB2-A3F3-75FE5955DECE

P698

Q21131585-59DA7EDF-52A6-4BFE-8D74-310709C023A2

P921

Q21131585-12ACB0D2-4695-4C5C-A7A4-6BDB1E83F8E0

Q21131585-A34C88CF-983D-430E-BF84-BC2083BB2415

P932

Q21131585-B2073A18-34EF-476F-8E09-E4A57511B3F2

P356

JOURNAL.PPAT.1000225

P1433

P1476

Vesicular stomatitis virus-bas ...... ocompromised nonhuman primates

@en

P2093

Anders Leung

http://www.w3.org/2001/XMLSchema#string

Jason Paragas

http://www.w3.org/2001/XMLSchema#string

Joan B Geisbert

http://www.w3.org/2001/XMLSchema#string

Kathleen M Daddario-Dicaprio

http://www.w3.org/2001/XMLSchema#string

Lennox Matthias

http://www.w3.org/2001/XMLSchema#string

Mark A Smith

http://www.w3.org/2001/XMLSchema#string

Mark G Lewis

http://www.w3.org/2001/XMLSchema#string

Steven M Jones

http://www.w3.org/2001/XMLSchema#string

P2860

Effective post-exposure treatment of Ebola infection

Development of a new vaccine for the prevention of Lassa fever.

The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?

The cell-rounding activity of the vesicular stomatitis virus matrix protein is due to the induction of cell death

Attenuated vesicular stomatitis viruses as vaccine vectors

Vaccine To Confer to Nonhuman Primates Complete Protection against Multistrain Ebola and Marburg Virus Infections

Development of a preventive vaccine for Ebola virus infection in primates

Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs

The glycoprotein of vesicular stomatitis virus is the antigen that gives rise to and reacts with neutralizing antibody.

Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys

P304

e1000225

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PPAT.1000225

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Peter B. Jahrling

Thomas W Geisbert

P577

2008-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23556517

http://www.w3.org/2001/XMLSchema#string

P698

19043556

http://www.w3.org/2001/XMLSchema#string

P921

Vaccine against Ebola

P932

2582959

http://www.w3.org/2001/XMLSchema#string